Pilot Study of Saquinavir and Lopinavir/Ritonavir Twice Daily in Protease Inhibitor-Naive HIV-Positive Patients

REFERENCES

• Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleo-side analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis. 2000;13:5–11.
   Google Scholar
• Haylir DV, Currier JS. Complications of HIV infection and antiretroviral therapy. Top HIV Med. 2003;11:86–91.
   PubMedGoogle Scholar
• Shikuma CM, Shiramizu B. Mitochondrial toxicity associ-ated with nucleoside reverse transcriptase inhibitor therapy. Curr Infect Dis Rep. 2001;3: 553–560.
   PubMedGoogle Scholar
• Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393–1401.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse tran-scriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 200115: 847–855.
   Google Scholar
• Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999;13:213–224.
   PubMed Web of Science ®Google Scholar
• Cameron DW, Angel JB, Ryan J, et al. Durability of ritonavir (RTV) plus saquinavir (SQV) dual protease inhibitor therapy in HIV infection: five-year follow-up. In: Program and ab-stracts of the 9th Conference on Retroviruses and Oppor-tunistic Infections; Seattle. Abstract 550–T.
   Google Scholar
• Cohen C, Shen Y, Rode R, et al. Effect of nucleoside (NRTI) intensification on prevalence of morphologic abnormalities (MoAs) at year 5 of ritonavir (RTV) plus saquinavir (SQV) therapy in an HIV-infected cohort. In: Program and ab-stracts of the 9th Conference on Retroviruses and Oppor-tunistic Infections; Seattle. Abstract 683–T.
   Google Scholar
• Boffito M, Moyle GJ. Pharmacokinetic considerations for com-bining 2 protease inhibitors. AIDS Read. 2004;14:110–116.
   PubMedGoogle Scholar
• Molla A, Mo H, Vasavanonda S, et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother. 2002;46:2249–2253.
   PubMed Web of Science ®Google Scholar
• Dam E, Rochas S, Faudon JL, et al. Synergistic activity of lopinavir and saquinavir on protease inhibitor-resistant HIV-1. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; San Fran-cisco. Abstract 622.
   Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resis-tance mutations in HIV-1. Top HIV Med. 2003;11:215–221.
   PubMedGoogle Scholar
• Parkin NT, Lie YS, Hellmann N, et al. Phenotypic changes in drug susceptibility associated with failure of human im-munodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis. 1999;180:865–870.
   PubMed Web of Science ®Google Scholar
• Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS. 2004; 18:503–508.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Scott U. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs. 2003;63:1299–1324.
   PubMed Web of Science ®Google Scholar
• Hellinger J, Morris AB, Piscitelli S, et al. Pilot study of saquinavir-SGC (Fortovase, SQV) 1000 mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-ex-perienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ). In: Program and ab-stracts of the 9th Conference on Retroviruses and Oppor-tunistic Infections; Seattle. Abstract 451–W.
   Google Scholar
• Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis. 2003;188:977–985.
   PubMed Web of Science ®Google Scholar
• Smith GHR, Klien MB, Murphy T, et al. Double, boosted salvage therapy with lopinavir(LOP)/ritonavir(RIT) and saquinavir-sgc(SQR) in HIV-1 infected patients having failed 3 antiretroviral classes. In: Program and abstracts of the XIV International AIDS Conference; Spain; Barcelona. Abstract TuPeB4547.
   Google Scholar
• Staszewski S, Dauer B, Carlebach A, et al. The LOPSAQ salvage study: 48 week analysis of the full cohort treated with lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy. In: Program and abstracts of the XV International AIDS Conference; July 11–16, 2004; Thailand; Bangkok. Abstract B10840.
   Google Scholar
• National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cho-lesterol in Adults (Adult Treatment Panel III). 2002. Avail-able at: http://www.nhIbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed November 11, 2004.
   Google Scholar
• Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 2003;4:94–100.
   PubMedGoogle Scholar
• Cardiello PG, Monhaphol T, Mahanontharit A, et al. Phar-macokinetics of once-daily saquinavir hard-gelatin cap-sules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. JAcquir Immune Defic Syndr. 2003;32:375–379.
   PubMed Web of Science ®Google Scholar
• Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003; 361:726–735.
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human im-munodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627.
   PubMed Web of Science ®Google Scholar
• Back D, Blaschke T, Boucher C, et al. Optimising TDM in HIV clinical care: a practical guide to performing therapeu-tic drug monitoring (TDM) for antiretroviral agents. Version 1.0. 2003. Available at: http://www.hivpharmacology.com. Accessed November 22, 2004.
   Google Scholar
• Gathe JC, Washington MY, Mayberry C, Piot D, Nemecek J. IMANI-1 TC3WP Single drug HAART- proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/ r) as single drug HAART in HIV + ARV-naive patients-interim analysis of subjects completing final 48 week data. In: Program and abstracts of the XV International AIDS Conference; July 11–16, 2004; Thailand; Bangkok. Ab-stract MoOrB1057.
   Google Scholar
• Pierone G, Mieras J, Kantor C, Bulgin-Coleman D, Shearer J, McCabe J. Lopinavir/r as sole therapy for HIV infection. In: Program and abstracts of the 9th European AIDS Confer-ence; October 25–29, 2003; Warsaw, Poland. Abstract F–1/5.
   Google Scholar
• Arribas JR, Pulido F, Lorenzo A, et al. Single-drug HAART (lopinavir/ritonavir) for maintenance of viral suppression: week 24 results of a randomized, open label, pilot clinical trial only Katetra study (OK). In: Program and abstracts of the XV International AIDS Conference; July 11–16, 2004; Bangkok, Thailand. Abstract TuBe4486.
   Google Scholar
• Smith GHR, Klein M, LeBlanc R, et al. Salvage therapy for HIV-1 infection with lopinavir/ritonavir (LOP/RIT), saquinavir-sgc (SQR), and nucleoside analogues in pa-tients having failed all three antiretroviral classes. Can J Infect Dis. 200112:29B.
   Google Scholar
• Roche Pharmaceuticals. Inv/rase Prescribing Information. 2003.
   Google Scholar
• Bertz R, Ashbrenner E, Foit C, et al. Assessment of the steady-state pharmacokinetics of three dosing regimens of saquinavir (400, 600 and 800 mg twice daily) administered as the hard gelatin capsule (HGC) in combination with lopinavir/ritonavir (LPV/r) 400/100 mg BID in HIV-infected adults. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy; Italy; Rome. Abstract 4.6.
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. A summary of implications of recent clinical trials for the National Choles-terol Education Program Adult Treatment Panel III guide-lines. Arterioscler Thromb Vasc Biol. 2004;24:1329–1330.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193.
   PubMed Web of Science ®Google Scholar
• Martinez E, Domingo P, Galindo MJ, et al. Risk of meta-bolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis. 2004;38:1017–1023.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Benetucci J, Brutus N, et al. on behalf of the MaxCmin2 trial group. Lipid profiles of patients enrolled in the MaxCmin2 trial: a randomized, open-label, multicenter comparative trial evaluating the safety and efficacy of lopinavir/ritonavir (LPV/r; 400/100 mg bid) versus saquinavir/ritonavir (SAQ/r; 1000/100 mg bid). In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; San Francisco. Abstract 720.
   Google Scholar
• Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641–649.
   PubMed Web of Science ®Google Scholar
• Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmaco-kinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodefi-ciency virus-negative adults. Antimicrob Agents Chemother. 2000;44:2672–2678.
   PubMed Web of Science ®Google Scholar
• Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS. 1998;12:1645–1651.
   PubMed Web of Science ®Google Scholar
• Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy expendi-ture among HIV-seropositive persons receiving highly ac-tive antiretroviral therapy. AIDS. 1999;13:1351–1357.
   PubMed Web of Science ®Google Scholar
• Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP. Clinical evaluation and management of metabolic and mor-phologic abnormalities associated with human immunode-ficiency virus. Clin Infect Dis. 2002;34:248–259.
   PubMed Web of Science ®Google Scholar